TAGRISSO as a second treatment

TAGRISSO may be an option as a second treatment

TAGRISSO may be an option if your first treatment stops working

If you're taking a targeted therapy known as a tyrosine kinase inhibitor (TKI) and your EGFR lung cancer progresses, TAGRISSO may be right for you.

What happens when lung cancer changes

EGFR+ lung cancer can change and try to outsmart the treatments you are taking

Cancer can become resistant, and your current TKI may stop working

If your cancer changes and develops another EGFR mutation called T790M, TAGRISSO may be an option for you

TAGRISSO is the only treatment that targets the EGFR T790M mutation. Talk to your doctor about your options, and ask if TAGRISSO may be right for you.

TAGRISSO as a second treatment compared to chemotherapy

In a clinical study, 279 people took TAGRISSO and 140 people received chemotherapy.

TAGRISSO may help you live significantly longer without tumors growing or spreading

TAGRISSO increased the chance of living without tumors growing or spreading by 70% compared with chemotherapy.

The median time that people lived without tumors growing or spreading was more than twice as long with TAGRISSO compared with chemotherapy (10.1 months on TAGRISSO compared with 4.4 months with chemotherapy).

TAGRISSO may help shrink tumors

More than 6 out of 10 people taking TAGRISSO had their tumors shrink compared with 3 out of 10 people receiving chemotherapy.*

TAGRISSO as a second treatment

*65% of people taking TAGRISSO compared with 29% of people receiving chemotherapy.

TAGRISSO may help with tumors in the brain

46 people who had tumors spread to the brain before the study were evaluated to see how TAGRISSO affected their brain tumors: 57% of those taking TAGRISSO and 25% of those receiving chemotherapy saw their brain tumors shrink.

Cancer that started in the lungs and has spread to other parts of the body such as the liver or brain. Often referred to as stage IV cancer.

A protein found on the surface of some cells. When EGFR mutates, it plays a role in causing cancer cells to grow excessively and spread as tumors. EGFR is one of the NSCLC biomarkers.

One of two main types of lung cancer. NSCLC is the most common.

A cancer treatment that is designed to work specifically on the processes that cancer uses to grow rapidly and spread.

A substance that prevents enzymes called tyrosine kinases from working. These enzymes are involved in the growth and division of cells, including cancer cells. TKIs are a type of targeted therapy.

A disease in which abnormal cells divide out of control, at a very fast rate. These abnormal cells can spread to other nearby organs and tissues.

A mutation that develops in EGFR+ NSCLC and causes the cancer to become resistant to the treatment being used (often a tyrosine kinase inhibitor or TKI).

When cancer cells are no longer harmed by the drugs used to kill or disrupt them. Tumors can be resistant from the start of treatment or become resistant during the course of treatment.

An abnormal growth of cells that may be benign (not cancer) or malignant (cancer).

Drug therapy that can kill cancer cells or stop them from dividing.

The middle number in a group of numbers arranged from lowest to highest.

Important Safety Information

TAGRISSO may cause serious side effects, including:

  • lung problems. TAGRISSO may cause lung problems that may lead to death. Symptoms may be similar to symptoms from lung cancer. Tell your doctor right away if you have any new or worsening lung symptoms, including trouble breathing, shortness of breath, cough, or fever
  • heart problems, including heart failure. TAGRISSO may cause heart problems that may lead to death. Your doctor should check your heart function before you start taking TAGRISSO and during treatment as needed. Tell your doctor right away if you have any of the following signs and symptoms of a heart problem: feeling like your heart is pounding or racing, shortness of breath, swelling of your ankles and feet, feeling lightheaded
  • eye problems. TAGRISSO may cause eye problems. Tell your doctor right away if you have symptoms of eye problems which may include watery eyes, sensitivity to light, eye pain, eye redness, or vision changes. Your doctor may send you to see an eye specialist (ophthalmologist) if you get eye problems with TAGRISSO
Important Safety Information

TAGRISSO may cause serious side effects, including:

  • lung problems. TAGRISSO may cause lung problems that may lead to death. Symptoms may be similar to symptoms from lung cancer. Tell your doctor right away if you have any new or worsening lung symptoms, including trouble breathing, shortness of breath, cough, or fever
  • heart problems, including heart failure. TAGRISSO may cause heart problems that may lead to death. Your doctor should check your heart function before you start taking TAGRISSO and during treatment as needed. Tell your doctor right away if you have any of the following signs and symptoms of a heart problem: feeling like your heart is pounding or racing, shortness of breath, swelling of your ankles and feet, feeling lightheaded
  • eye problems. TAGRISSO may cause eye problems. Tell your doctor right away if you have symptoms of eye problems which may include watery eyes, sensitivity to light, eye pain, eye redness, or vision changes. Your doctor may send you to see an eye specialist (ophthalmologist) if you get eye problems with TAGRISSO

Before taking TAGRISSO, tell your doctor about all of your medical conditions, including if you:

  • have lung or breathing problems
  • have heart problems, including a condition called long QTc syndrome
  • have problems with your electrolytes, such as sodium, potassium, calcium or magnesium
  • have a history of eye problems
  • are pregnant or plan to become pregnant. TAGRISSO can harm your unborn baby. Tell your doctor right away if you become pregnant during treatment with TAGRISSO or think you may be pregnant
    • Females who are able to become pregnant should use effective birth control during treatment with TAGRISSO and for 6 weeks after the final dose of TAGRISSO
    • Males who have female partners that are able to become pregnant should use effective birth control during treatment with TAGRISSO and for 4 months after the final dose of TAGRISSO
  • are breastfeeding or plan to breastfeed. It is not known if TAGRISSO passes into your breast milk. Do not breastfeed during treatment with TAGRISSO and for 2 weeks after your final dose of TAGRISSO. Talk to your doctor about the best way to feed your baby during this time

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Especially tell your doctor if you take a heart or blood pressure medicine

The most common side effects of TAGRISSO are:

  • diarrhea
  • rash
  • dry skin
  • changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from nailbed, and shedding of nails
  • mouth sores
  • tiredness
  • decreased appetite

Tell your doctor if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of TAGRISSO. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-fda-1088.

What is TAGRISSO?

TAGRISSO is a prescription medicine for non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic). TAGRISSO is used:

  • as a first treatment if tumors have a certain abnormal epidermal growth factor receptor (EGFR) gene(s)
  • or
  • for a certain type of EGFR gene that has been treated with an EGFR tyrosine kinase inhibitor (TKI) medicine that did not work or is no longer working

Your doctor will perform a test to make sure that TAGRISSO is right for you.

It is not known if TAGRISSO is safe and effective in children.

Please see full Prescribing Information including Patient Information.

You may report side effects related to AstraZeneca products by clicking here.